Potential Antiviral Lignans from the Roots of Saururus chinensis with Activity against Epstein-Barr Virus Lytic Replication

被引:58
|
作者
Cui, Hui [1 ]
Xu, Bo [2 ]
Wu, Taizong [1 ]
Xu, Jun [1 ]
Yuan, Yan [2 ,3 ]
Gu, Qiong [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery, Guangzhou 510006, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Human Virol, Guangzhou 510080, Guangdong, Peoples R China
[3] Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA
来源
JOURNAL OF NATURAL PRODUCTS | 2014年 / 77卷 / 01期
基金
中国国家自然科学基金;
关键词
NASOPHARYNGEAL CARCINOMA; TETRAHYDROFURAN LIGNANS; ABSOLUTE-CONFIGURATION; INHIBITORY-ACTIVITY; PIPER-SOLMSIANUM; ACTIVATION; NEOLIGNANS; SESQUILIGNANS; CONSTITUENTS; MANASSANTIN;
D O I
10.1021/np400757k
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Epstein-Barr virus (EBV) is a member of the gamma-herpes virus subfamily and has been implicated in the pathogenesis of several human malignancies. Bioassay-guided fractionation was conducted on an EtOAc-soluble extract of the roots of Saururus chinensis and monitored using an EBV lytic replication assay. This led to the isolation of 19 new (1-19) and nine known (20-28) lignans. The absolute configurations of the new lignans were established by Mosher's ester, ECD, and computational methods. Eight lignans, including three sesquineolignans (19, 23, and 24) and five dineolignans (3, 4, 26, 27, and 28), exhibited inhibitory effects toward EBV lytic replication with EC50 values from 1.09 to 7.55 mu M and SI values from 3.3 to 116.4. In particular, manassantin B (27) exhibited the most promising inhibition, with an EC50 of 1.72 mu M, low cytotoxicity, CC50 > 200 mu M, and SI > 116.4. This is the first study demonstrating that lignans possess anti-EBV lytic replication activity.
引用
收藏
页码:100 / 110
页数:11
相关论文
共 36 条
  • [1] Cardiac glycosides from the roots of Streblus asper Lour. with activity against Epstein-Barr virus lytic replication
    Cai, Jing
    Zhang, Bo-Dou
    Li, Yu-Qi
    Zhu, Wan -Fang
    Akihisa, Toshihiro
    Kikuchi, Takashi
    Xu, Jian
    Liu, Wen -Yuan
    Feng, Feng
    Zhang, Jie
    BIOORGANIC CHEMISTRY, 2022, 127
  • [2] Epstein-Barr virus lytic replication and cancer
    Li, Hao
    Lee, Chih-Ying
    Delecluse, Henri-Jacques
    CURRENT OPINION IN VIROLOGY, 2025, 70
  • [3] Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus
    Wu, Ting
    Wang, Yan
    Yuan, Yan
    ANTIVIRAL RESEARCH, 2014, 107 : 95 - 101
  • [4] Replication Compartments-The Great Survival Strategy for Epstein-Barr Virus Lytic Replication
    Sugimoto, Atsuko
    MICROORGANISMS, 2022, 10 (05)
  • [5] Lytic replication of Epstein-Barr virus in human peripheral T-lymphocytes
    Ninla-aesong, Putrada
    Pradutkanchana, Jintana
    Noipha, Kusumarn
    Mitarnun, Winyou
    ASIAN BIOMEDICINE, 2010, 4 (02) : 207 - 214
  • [6] Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation
    Huang, Lu
    Yang, Mengtian
    Yuan, Yan
    Li, Xiaojuan
    Kuang, Ersheng
    ANTIVIRAL RESEARCH, 2017, 138 : 68 - 78
  • [7] Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus
    Goswami, R.
    Gershburg, S.
    Satorius, A.
    Gershburg, E.
    ANTIVIRAL RESEARCH, 2012, 96 (03) : 296 - 304
  • [8] Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate early lytic promoters
    Wang, Man
    Wu, Wei
    Zhang, Yinfeng
    Yao, Guoliang
    Gu, Bianli
    VIRUS RESEARCH, 2018, 244 : 173 - 180
  • [9] Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future
    Yiu, Stephanie Pei Tung
    Dorothea, Mike
    Hui, Kwai Fung
    Chiang, Alan Kwok Shing
    CANCERS, 2020, 12 (08) : 1 - 23
  • [10] Cellular MicroRNAs 200b and 429 Regulate the Epstein-Barr Virus Switch between Latency and Lytic Replication
    Ellis-Connell, Amy L.
    Iempridee, Tawin
    Xu, Iris
    Mertz, Janet E.
    JOURNAL OF VIROLOGY, 2010, 84 (19) : 10329 - 10343